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Abstract IRF-1, a kind of transcription factor, is expressed in
many cell types, except in early embryonal cells. IRF-1 has
played an essential role in various physiological and patho-
logical processes, including tumor immune surveillance, viral
infection, development of immunity system and pro-
inflammatory injury. However, the expression and function
of IRF-1 in spinal cord injury (SCI) are still unknown. In this
study, we have performed an acute SCI model in adult rats and
investigated the dynamic changes of IRF-1 expression in the
spinal cord. Western blot have shown that IRF-1 protein levels
gradually increased, reaching a peak at day 3 and then gradu-
ally declined to a normal level at day 14 after SCI. Double
immunofluorescence staining showed that IRF-1 immunore-
activity was found in neurons, but not in astrocytes and mi-
croglia. Additionally, colocalization of IRF-1/active caspase-3
was detected in neurons. In vitro, IRF-1 depletion, by short
interfering RNA, obviously decreases neuronal apoptosis. In
conclusion, this is the first description of IRF-1 expression in
spinal cord injury. Our results suggested that IRF-1 might play
crucial roles in CNS pathophysiology after SCI.
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Abbreviations
IRF-1 Interferon regulatory factor-1
SCI Spinal cord injury
CNS Central nervous system
SD Sprague–Dawley
NeuN Neuronal nuclear antigen
GFAP Glial fibrillary acidic protein
IBa1 Ionized calcium-binding adapter molecule 1
siRNA Short interfering RNA
Introduction
Spinal cord injury is characteristically accompanied by a pe-
riod of secondary cell degeneration, which occurs in injured
tissue over a course of time after the initial damage and lead to
neuronal death, microglial activation, inflammation, and reac-
tive astrogliosis (Crowe et al. 1997; Dumont et al. 2001; Liu
et al. 1997; McGraw et al. 2001). The primary injury is attrib-
uted to the initial mechanical insult due to the direct tissue
damage and energy transformation (Tator 1996). The second-
ary injury may result from spinal cord edema, ischemia, free
radical damage, electrolyte imbalance, excitotoxicity, inflam-
matory injury, or apoptosis. These factors cause neuronal cell
death, astrocyte proliferation, and reactive gliosis, resulting in
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the formation of a dense astrocytic scar (McGraw et al. 2001;
Raghupathi 2004). The apoptosis of post-mitotic cells, such as
neurons occurring after the spinal cord injury, may lead to
subsequent neurological dysfunction (Di Giovanni et al.
2003). Simultaneously, glial scar provides a physical and bio-
chemical barrier to regeneration and plasticity, and it is a
source of multiple inhibitory factors that affect functional re-
covery from spinal cord injury (SCI) (Davies et al. 1996;
Silver and Miller 2004). However, the signaling events that
contribute to neuronal apoptosis and glial scar after SCI re-
main to be further researched.
IRF-1, the primary member of the interferon (IFN) regula-
tory factor family, was initially identified as a key regulator of
type I interferon (α/β). The IRF-1 messenger RNA is
expressed in cell cycle-dependent accumulation at a low base
level in many cell types except early embryonal cells
(Watanabe et al. 1991). Recently, IRF-1 has been found par-
ticipating in signal transduction of other ligands, including
tumor necrosis factor and interleukin-12 (Galon et al. 1999),
interleukin-1β (Geller et al. 1993), and CD40 ligand (Gupta
et al. 1998). In addition, some studies have shown that IRF-1
may function as a potential tumor suppressor (Tanaka et al.
1994), such as that the loss of IRF-1 contributes to tumor
development in conjunction with c-Ha-ras in vivo (Nozawa
et al. 1999). IRF-1 is also connected with apoptosis induced
by DNA damage or other stimuli. DNA damage causes apo-
ptosis in mitogenically activated mature T lymphocytes which
is dependent on IRF-1 instead of p53. In addition, IRF-1 in-
duces apoptosis by the intrinsic pathway, instead of the extrin-
sic pathway, by increasing the expression of p53 unregulated
modulator (PUMA) (Gao et al. 2010). However, in thymo-
cytes, apoptosis is lived on p53 but not on IRF-1. Thus, the
role of IRF-1 and p53 in regulating DNA damage-induced
apoptosis is both cooperative and independent, depending
on the type and different stage of the cell (Lallemand et al.
2002). Previous studies have demonstrated the important role
of IRF-1 in cell apoptosis; whether IRF-1 could affect the
apoptosis of neurons after SCI or not remains unclear.
In this study, we investigated temporal-spatial patterns of
IRF-1at protein level and its colocalization with active
caspase-3 using an acute SCI model on adult rats. The above
data suggest that IRF-1 is involved in pathophysiological and
biochemical progression after SCI. Our experiments were con-
ducted to gain an insight into the functions of IRF-1 and its role in
the cellular andmolecularmechanisms underlying SCI and repair.
Materials and Methods
Spinal Cord Injury
Experiments were performed in accordance with the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals; all animal experiments were allowed
by the Department of Animal Center, Medical College of
Nantong University. Surgery male Sprague–Dawley (SD) rats
(n = 48) with an average body weight of 250 g were subjected
to SCI. The SD rats were deeply anesthetized by sodium pen-
tobarbital (65 mg/kg, i.p.), and the surgery was operated under
aseptic conditions. A laminectomy was performed at the level
of the 9th thoracic vertebrae to expose a circle of dura mater.
The contusion injuries (n = 40) were used by the NYU
Fig. 1 Change of IRF-1 expression at protein level following spinal cord
injury. a Sample immunoblots detected for IRF-1 and GAPDH are
shown. b Expression levels of IRF-1 were normalized against GAPDH,
as estimated by optical density measurements. c AWestern blot analysis
was performed for the 3d protein in different quantities and then
performed an actual calibration curve of the Western blot results, and
when the densitometric intensity of the measured values in Fig. 1a was
brought into the curve, the result indicate an about 6-fold increase in IRF-
1 protein expression after SCI. The data are represented as means ± SEM
(n = 3 rats per time point; *P < 0.05, significantly different from the sham-
injured group)
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impactor; the exposed rat’s spinal cord was impacted by
dropping a bar 10 g in weight and 2.0 mm in diameter from
a height of 10 cm. The control group animals (n = 8) were
anesthetized and surgically planned, but not undergo a spinal
cord injury. The animals were permitted to recover on a 30 °C




rat spinal cord. Low-power views
of transverse sections
immunostained for IRF-1 in
sham-operated spinal cord (a) and
3 days after injury (b). High-
power views in the dorsal top (c,
d) and in the ventral bottom (e, f).
Immunostaining of IRF-1 shown
that IRF-1 expression increases in
the dorsal top (d) and ventral
bottom (f) after injury. Bars
200 μm (a, b), 20 μm (c–f).
Quantitative analysis of IRF-1-
positive cells/mm2 in sham-
operated rats and 3 days after SCI
(g), indicating a obviously
increase after SCI compare with
sham-operated animals (n = 3 in
sham-operated group, n = 3 in
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(2.0 cm3, s.c.) for rehydration and Baytril (0.3 cm3,
22.7 mg/ml, s.c., twice daily) to prevent infection. The ani-
mals were sacrificed at 6 to 12 h and 1, 3, 5, 7 and 14 days
after injury. Eight naive animals were used as non-injured
controls. All efforts were made to decrease the number of
animals used and their inflicting pain.
Western Blot Analysis
In order to get samples for Western blot analysis, the sham or
injured spinal cords were taken out and cryopreserved at
−80 °C for further use later. The portion of the spinal cord
extending from 5 mm caudal to 5 mm rostral in the injury
epicenter was immediately removed. To make the lysates,
the frozen spinal cord samples were minced with eye scissors
on ice. The samples were then well-distributed in lysis buffer
(50 mmol/l Tris, 1 % NP-40, pH 7.5, 1 % SDS, 5 mmol/l
EDTA, 1 % sodium deoxycholate, 1 mmol/l PMSF, 1 % Tri-
ton X-100, 1 mg/ml leupeptin, and 10 mg/ml aprotinin) and
clarified by centrifugation for 20 min in a microcentrifuge at
4 °C. After the determination of its protein concentration with
the Bradford assay (Bio-Rad), the resulting supernatant (50μg
of protein) was accepted to SDS–polyacrylamide gel electro-
phoresis (PAGE). Then, the separated proteins were trans-
ferred to a polyvinylidine difluoride membrane (Millipore)
by a transfer apparatus at 350 mA for 2.5 h and blocked with
5 % nonfat milk. The membrane was incubated with primary
antibodies against IRF-1 (anti-rabbit, 1:1000; Santa Cruz),
active caspase-3 (anti-rabbit, 1:1000; Cell Signaling), and
GAPDH (anti-rabbit, 1:1000; Santa Cruz). After incubating
with an anti-mouse or anti-rabbit horseradish peroxidase-
conjugated secondary antibody, the protein was visualized
by an enhanced chemiluminescence system (ECL, Pierce
Company, USA).
Immunohistochemistry and Immunofluorescent
After the different time decided, the sham and injured rats
were terminally anesthetized and perfused through the ascend-
ing aorta with saline and next with 4 % paraformaldehyde.
After perfusion, the sham and injured spinal cords were
post-fixed in 4 % paraformaldehyde for 12 h and then dehy-
dration in sucrose. After treatment with sucrose solutions, the
spinal cords were embedded in O.T.C. compound. Next, they
were cut into 4.5-μm frozen cross sections at two spinal cord
levels, prepared, and examined. All of the sections were
blocked with 10 % Donkey serum with 0.3 % Triton X-100
and 1 % (w/v) bovine serum albumin (BSA) for 2 h at RT and
incubated overnight at 4 °C with anti-IRF-1 antibody (anti-
rabbit, 1:100; Santa Cruz), followed by incubation in biotinyl-
ated secondary antibody (Vector Laboratories, Burlingame,
CA, USA). Staining was visualized with DAB (Vector Labo-
ratories). Cells with strong or moderate brown staining were
counted as positive; cells with no staining were counted as
negative; while cells with weak staining were scored
separately.
For double immunofluorescent staining, sections were re-
moved from the freezer and incubated in an oven at 37 °C for
40 min. The sections were incubated with rabbit polyclonal
primary antibodies for IRF-1 (1:100), NeuN (neuron marker,
1:100), DAPI (nucleus marker 1:1000), GFAP (astrocytes
marker, 1:100), and IBa1 (microglia marker, 1:100). Briefly,
sections were incubated with both primary antibodies over-
night at 4 °C, followed by a mixture of CY2- and CY3-
conjugated secondary antibodies for 2 h at 25 °C. The stained
sections were examined with a Leica fluorescence microscope
(Germany).
Rat Primary Neurons
Both spinal cords were removed from the 1-day-old Sprague–
Dawley rat pups, and the tissues were gently minced by for-
ceps and then dissociated by incubating at 37 °C for 30 min,
with occasionalmixing, in 10ml of phosphate-buffered saline.
After centrifugation at 1200 rpm for 5 min, the tissues were
removed in 5 ml DMEM containing 10 % FBS and gently
aspirated several times to inactivate the trypsin. The proce-
dures were carried out similarly to those previously described.
After the medium had been decanted, the cells were resus-
pended in a Neurobasal medium. Cells were plated at a den-
sity of 4 × 104 cells/ml on poly-L-lysine-coated 6-well culture
plates. Before the experimental treatments, cells were grown
for 8 days to induce apoptosis by using glutamate.
ShRNA and Transfection
ShRNA IRF-1 corresponding to nucleotide sequences (5′-
T G T G G A T C T T G C C A C A T T T - 3 ′ , 5 ′ -
TCTGTCTATGGAGACTTTA -3 ′). PC12cells were
transfected with specific shRNA IRF-1 or negative control,
and the efficacy of IRF-1 inhibition was tested by Western
blot analysis. Cells were transfected transiently with plasmid
DNA using 10 μl Lipofectamine 2000 according to the man-
ufacturer’s recommendations. Transfected cells were used for
the subsequent experiments 48 h after transfection.
Fig. 3 Immunofluorescence staining for IRF-1 and different phenotype-
specific markers in spinal cord of adult rats examined at 2.5 mm to the
epicenter at day 3 after injury. a–r Tissue sections were immunolabeled
with IRF-1 (red) and phenotype-specific markers (green), namely NeuN,
GFAP, and IBa1. Merge of IRF-1 and phenotype-specific markers
(yellow) is shown in the gray matter (a–f) and white matter (g–r). Bar
20 μm. s Quantitative analysis of cells co-expressing various phenotype-
specific markers and IRF-1 (%) in gray matter and white matter. Changes
of IRF-1 expression after SCI were increased in neurons (n = 3 in sham-
injured group, n = 3 in injured group; *significant difference at P < 0.05
compared with sham-injured rats; error bars SEM)
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Annexin-V/PI Analysis of Primary Neurons Apoptosis
After the indicated treatment, primary neurons were digested
using trypsin and suffered apoptotic analysis by Annexin-V-
FLUOS staining kit (Roche Diagnostics, Basel, Switzerland)
obeying the manufacturer’s instructions.
Quantitative Analysis
The number of IRF-1-positive cells in the spinal cord 2.5 mm
rostral to the epicenter was counted in a 500 × 500-μm mea-
suring frame. For each animal, a measure was taken from a
section through the dorsal horn, the lateral funiculus, and the
ventral horn. In order to avoid counting the same cell in more
than one section, we counted every fifth section (50 μm apart).
The cell counts were used to determine the total number of
IRF-1-positive cells per square millimeter. We simultaneously
quantified the percentage of cells with IRF-1 staining. Cells
double-labeled for IRF-1 and other phenotypic markers were
quantified too. To identify the proportion of each phenotype-
specific marker-positive cells expressing IRF-1, a minimum
of 200 phenotype specific marker-positive cells were counted
in both the white matter and gray matter in each section, with
the exception that NeuN is only conducted in the gray matter.
We then recorded the number of cells double-labeled with
IRF-1 and a cell-specific marker. Two or three adjacent sec-
tions per animal were sampled at 2.5 mm from the epicenter.
Statistical Analysis
All data was analyzed with the Stata 7.0 statistical soft-
ware. All values were expressed as the mean ± SEM.
One-way ANOVA followed by Tukey’s post hoc multi-
ple comparison tests were used for the statistical analy-
sis. P values less than 0.05 were considered statistically
significant. Each experiment consisted of at least three
replicates per condition.
Result
Expression Profiles of IRF-1 Following SCI
To investigate the expression pattern of IRF-1, a West-
ern blot analysis was performed followed by the spinal
cord injury. IRF-1 protein level was low in sham-
operated spinal cords (sham) and gradually increased
in the first 12 h after injury, reached a peak at day 3.
After 14 days, IRF-1 expression returned to the level of
sham-operated spinal cords (Fig. 1a, b). These results
suggested that IRF-1 protein might be upregulated by
an injury. In order to better understand the changes of
IRF-1, we calibrate the densitometer by running a
dilution series of protein added (by increasing dilutions
of the protein extract with the 3d protein), a Western
blot analysis was performed for the protein in different
quantities, then measured the densitometric intensity,
and set the densitometric intensity of 20 μ protein as
1.0. According to the measured values, we performed an
actual calibration curve, and when the densitometric in-
tensity of the measured values in Fig. 1a was brought
into the curve, the result indicates an about 6-fold in-
crease in IRF-1 protein expression after SCI. (Fig. 1c).
The Expression and Distribution of IRF-1 in Sham
and Injured Spinal Cord Tissue
To identify the expression and distribution changes of IRF-1
after SCI, immunohistochemistry with anti-IRF-1 antibody on
transverse cryosections of the spinal cord was performed.
IRF-1 was extensively expressed in the gray matter which
usually indicated neurons, regardless of whether the spinal
cord tissues were sham or injured. Notably, in sham-
operated controls, immunostaining of IRF-1 was observed at
low levels (Fig. 2a, c, e). However, the staining was increased
after SCI (Fig. 2b, d, f). In addition, the number of IRF-1-
positive cells in dorsal top and ventral bottom was counted
and a significant difference was found between sham-operated
spinal cords at day 3 after injury, which was paralleled with
Western blot results (Fig. 2g).
The Colocalization of IRF-1 and Different
Phenotype-Specific Markers by Double
Immunofluorescent Staining
To further confirm the cellular localization of IRF-1, double
labeling immunofluorescent staining was shown with the fol-
lowing phenotype-specific markers: NeuN, GFAP, and IBa1
(Fig. 3a–r) in transverse cryosections of spinal cord within a 2-
mm distance from the epicenter. Notably, IRF-1 expression
was widely distributed in neurons and expression was signif-
icantly increased at 3 days after SCI, compared with the sham-
operated group (P < 0.05). However, IRF-1 expression was
not staining with astrocytes and microglia at sham-operated or
3 days after SCI (Fig. 3s).
Activated Caspase-3 and IRF-1 Immunoreactivity
in Injured Spinal Cords
Reports have shown that neuronal apoptosis had played
an important role in SCI. Then, Western blot analyses
were prepared to examine the expression of activated
caspase-3, which is a marker of apoptosis. Activated
caspase-3 expression was significantly increased at
3 days a f t e r SCI (F ig . 4a , b ) . To probe the
colocalization of IRF-1 with activated caspase-3 in
600 J Mol Neurosci (2015) 57:595–604
injured spinal cords, double-immunofluorescent staining
was performed. Colocalization of activated caspase-3
with IRF-1and NeuN was observed at 3rd day after
SCI (Fig. 4h, n). In addition, glial cells might also
cause apoptosis after SCI. We performed double-
immunofluorescent staining of active caspase-3 with
GFAP and IBa1. However, we could not find any
colocalization in control or injured groups (Fig. 4o–z).
These results indicate that IRF-1 might be associated
with neuronal apoptosis after SCI.
Fig. 4 Association of IRF-1 with apoptosis after SCI. aWestern blot was
analyzed for markers of apoptosis (active caspase-3) following SCI. bBar
chart showing the ratio of IRF-1 to GAPDH at each time point; the data
are means ± SEM (n = 3 rats per time point, *P < 0.05, significantly
d i f f e r en t f r om the sham- i n j u r ed g roup ) . c– z Doub l e -
immunofluorescence staining for IRF-1, NeuN, GFAP, and IBa1 with
active caspase-3 in spinal cord at day 3 after SCI. Tissue sections
labeled with active caspase-3 (red), NeuN or IRF-1 (green) are shown
in the gray matter. Bar 20 μm. z1Quantitative analysis of NeuN-, IRF-1-,
GFAP-, and IBa1-positive cells expressing active caspase-3 in percent
(n = 2 in sham-operated group, n = 3–5 in injured group; *P < 0.05,
significantly different from the sham-injured group)
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IRF-1 Knockdown Inhibits Neuronal Apoptosis
To investigate the effect of IRF-1 on neuronal apoptosis fur-
ther, a neuronal apoptosis model was established by using
glutamate to induce primary cultured neurons. Western blot
showed that IRF-1, P53,PUMA, BAX, and active caspase-3
expression were increased (Fig. 5a). Then, we used IRF-1-
specific siRNA to knockdown endogenous IRF-1 in primary
neurons. The efficiency of the IRF-1-siRNA was tested by
Western blot analysis. Western blot analysis showed IRF-1-
siRNA #2 markedly reduced the level of IRF-1 expression
compared with IRF-1-siRNA #1 (Fig. 5c). Furthermore, we
use Western blot to investigate the active caspase-3 protein
level and found that their expression were declined in IRF-1-
specific siRNA (IRF-1-siRNA #2) cells. Our result displayed
that siRNA reduced the protein levels of active caspase-3
Fig. 5 Effects of IRF-1-specific siRNA on glutamate-induced primary
neuron apoptosis. Cells were respectively transfected by nothing (normal
control), control-siRNA, IRF-1-siRNA#1, and IRF-1-siRNA#2 for 48 h,
then induced by glutamate (200 μM) for 12 h. aWestern blot analysis for
IRF-1, active caspase-3, in primary neurons after being induced by
glutamate for different points. b Bar chart showing the ratio of IRF-1,
active caspase-3, to GAPDH. c Efficiency of IRF-1-specific siRNA in
primary neurons. Western blot analysis showing that IRF-1-siRNA#2
treatment markedly decreases IRF-1 levels at 48 h after siRNA
transfection in neurons. d Bar chart showing the ratio of IRF-1 to
GAPDH. e Western blot analysis showing that IRF-1-siRNA#2
treatment markedly decreases active caspase-3 levels at 48 h after
siRNA transfection in neurons. f Bar chart showing the ratio of active
caspase-3 to GAPDH. g Primary neurons were respectively transfected
by nothing (normal control), control-siRNA, and IRF-1-siRNA#2 for
48 h, then on glutamate induction for 12 h, next subjected to flow
cytometrical analysis, cells were transfected by IRF-1-siRNA#2 shown
great role in reducing neuronal apoptosis. hBar chart showing the ratio of
the apoptosis of primary neurons (n = 9; *significant difference at
P < 0.05 compared with sham-injured rats; error bars SEM)
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compared with the control group (Fig. 5e). In order to further
understand the relationship between IRF-1 and apoptosis, we
use Annexin-V/PI to analyze apoptosis in primary neurons
which was induced by glutamate. We found that apoptosis
cells were obviously declined in IRF-1-siRNA#2 cells com-
pared with control group (Fig. 5g).
Discussion
Traumatic spinal cord injury is a devastating disorder and a
great financial burden on society. Recent studies suggest that
apoptosis play important roles in the mediation of secondary
SCI (Cheng et al. 2008). Thus, a further research of the apo-
ptosis after SCI is necessary. In the current study, for the first
time, we have revealed the expression profiles of IRF-1 after
traumatic SCI. Western blot and immunohistochemistry anal-
ysis showed that IRF-1 was upregulated after injury and
peaked at 3 days, and its expression was increased significant-
ly in neurons, while no significant changes were detected in
glial cells. In addition, expression patterns of P53,PUMA,
BAX, and activate caspase-3 were parallel with that of IRF-
1, which suggested the potential role of IRF-1 in regulating
neuronal apoptosis. Finally, siRNA experiment showed that
IRF-1 played an important role in regulating neuronal apopto-
sis in vitro. These data indicate that IRF-1 may participate in
neuronal apoptosis after SCI.
SCI is often seriously disabling people, primarily the
young, which brings a heavy burden in personal, financial,
and societal terms (Johnson et al. 1997). SCI leads to tissue
loss and associates with neurological dysfunction which
causes mechanical damage and secondary biochemical and
physiological responses (Dumont et al. 2001). Secondary in-
jury mechanisms include neuronal apoptosis, glial cell activa-
tion, scar formation, and so on (Tator 1996). Neuronal apo-
ptosis has an important role in secondary injury, diffusely
apoptosis of neurons has been found following SCI (Lu
et al. 2000) which are eliminated by the immune system and
form a cavity (Willyard 2013). Furthermore, research has
shown that the family of caspase played important roles in
spinal cord nerve apoptosis (Liu et al. 1997). The upregulation
of caspase family expression contributes to the spinal cord
secondary injury, and selective inhibition of caspase effective-
ly prevented spinal cord secondary injury (Wu et al. 2012).
Thus, further understanding of the neuronal apoptosis in SCI
can be useful for the treatment of SCI.
IRF-1 was the first member of IRFs family which was
discovered to activate promoters in type I IFN genes. It has
long been known that through IRF-1, many viruses can elicit
the induction of type I IFN gene in many cell types by the
activation of cytosolic PRRs (Yoneyama et al. 2004;
Yoneyama et al. 2005). As is known, caspases are unique
proteases that play important roles in an activation cascade
downstream in the apoptosis mechanism. Some research has
demonstrated that IRF-1 directly regulates the IFN-γ induced
apoptosis by activation of caspase-1 gene expression in
IFN-γ-sensitive ovarian cancer and other cancer cells (Kim
et al. 2002). What is more, IRF-1 participated in induction of
caspase-8 expression and apoptosis initiated by IFN-γ (Ruiz-
Ruiz et al. 2004). Recently, further studies have indicated
additional IRF-1 target genes. Activity of IRF-1 has been as-
sociated with downregulation of survivin (Pizzoferrato et al.
2004) and cyclin D1 (Kroger et al. 2007). Previous studies
have also demonstrated that IRF-1 is involved in injury in lots
of clinical setting, including ischemia–reperfusion injury (IR),
shock, and transplantation. In liver warm IR model, IRF-1
knockdown mice are protected from organ injury after IR
and that upregulation of IRF-1 results in liver damage even
in the absence of injury (Tsung et al. 2006).
In conclusion, the present researches have demonstrated
that IRF-1 expression changes after SCI suggesting that
IRF-1 participates in the regulation of biochemical and phys-
iological responses. Furthermore, knockdown of IRF-1 by
siRNA can decrease glutamate-induced apoptosis in primary
neurons. Our data may provide a novel insight for the treat-
ment of SCI. However, the clear mechanism of IRF-1 in reg-
ulating SCI still needs further research.
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